Skip to main content

Table 1 Characteristics of all the studies included in the meta-analysis

From: Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis

Study

Year

Country

Time

No.

Age (years)

Index and cut-off

Median follow-up (month)

Outcome

Yasui

2018

Japan

2011–2016

90

73.7 ± 0.9

NLR: 3.76

Unclear

OS

Fan

2018

China

2013–2017

104

72 (65.3–77.0)

NLR: 3

20.2

OS, PFS

Conteduca

2018

Italy

2011–2016

551

75 (42–91)

NLR: 3

18.4

OS, PFS

Vidal

2018

USA

1991–2015

1826

61.8 ± 5.9

NLR; lymphocyte; PLT; neutrophil; PLR

68

OS, RFS

Sun

2018

China

2011–2016

171

Unclear

NLR: 2.31; PLR:134

24

OS, DFS

Uemura

2017

Japan

2014–2016

47

71.0 ± 7.0

NLR: 3.83

Unclear

OS

Mehra

2017

UK

Unclear

75

Unclear

NLR: 2.6

25.6

OS, PFS

Boegemann

2017

USA

2009–2015

96

70 (63.0–76.3)

NLR: 5

20

OS, PFS

Pei

2017

China

2013–2017

111

71 (43–86)

NLR: 3.3

16

OS, PFS

Buttigliero

2017

Italy

Unclear

110

Unclear

NLR: 3

31.7

OS, PFS

Wang

2017

China

2010–2014

290

71 (65–77)

Monocyte:0.425

37.0

OS, PFS

Jang

2016

Korea

2000–2010

2067

66 (61–70)

NLR:1.76; lymphocyte, neutrophil

78

OS, RFS, CSS

Lolli

2016

Italy

2011–2015

230

74 (45–90)

NLR: 3; PLR:210

29

OS

Shigeta

2016

Japan

2007–2015

108

106

71 (57–88)

73 (52–95)

NLR: 3.8; LMR: 3.86; monocyte: 0.4

Unclear

OS, PFS

Lee

2016

Korea

Unclear

1367

65.6 (45–82)

NLR: 2.5

57

RFS

Wang

2016

China

2010–2014

290

75 (67–79)

Lymphocyte; PLT:190.5; PLR:117.58

37

OS, PFS, CSS

Langsenlehner

2015

Austria

1999–2007

415

66.9 ± 7.2

NLR: 5

87

OS, PFS, DMFS

Langsenlehner

2015

Austria

1999–2007

374

68 ± 7.1

NLR; PLT; PLR:190

87

OS, CSS, DMFS

Zhang

2015

China

2006–2009

237

Unclear

NLR: 2.36

46.6

RFS

Bahig

2015

Canada

2001–2014

950

Unclear

NLR; lymphocyte; neutrophil

44

OS, RFS

Lorente

2015

UK

Unclear

755

67 (62–73)

NLR: 3

12.8

OS, PFS

Yao

2015

Japan

2008–2014

57

74 (55–91)

NLR: 3.5

30

OS, PFS

Li

2015

China

2009–2012

103

Unclear

PLR:150

36

OS

McLachlan

2015

Austria

2005–2012

42

Unclear

NLR:5

23.1

OS

Sharma

2015

USA

1990–2007

8350

Unclear

NLR:5

116.4

OS, PFS, RFS, CSS

Templeton

2014

Canada

2001–2011

357

71.0 (44.0–90.0)

NLR: 3

Unclear

OS

Sonpavde

2014

UK

2008–2010

848

Unclear

NLR:2.5

Unclear

OS, RFS

Nuhn

2014

USA

1998–2010

238

68.3 (44.6–84.5)

NLR: 3

15.0

OS

Poyet

2013

Switzerland

2008–2013

399

64.0 (41.0–78.0)

NLR: 2.67

23.0

RFS

Linton

2013

Austria

2007–2009

184

Unclear

NLR: 5

Unclear

OS

Shafique

2012

UK

2000–2007

897

Unclear

NLR: 5

30

OS

Yamada

2011

Japan

1998–2006

104

74.2 ± 7.4

PLT

43

CSS

  1. OS overall survival, CSS cancer-specific survival, PFS progression-free survival, DMFS distant metastases-free survival, RFS recurrence-free survival, PLR platelet to lymphocyte ratio, NLR neutrophil to lymphocyte ratios, LMR lymphocyte to monocyte ratio, PLT platelet